Acadia EVP Executes Option Exercise, Sells Shares Worth About $73,749
Elizabeth H.Z. Thompson, Executive Vice President and Head of Research & Development at Acadia Pharmaceuticals, disclosed an option exercise and subsequent sale that generated roughly $73,749. The trades were reported on a Form 4 and follow corporate developments including a regulatory negative opinion on trofinetide in Europe, a brokerage upgrade,…